Allergan Shifts Restasis Patents To Native American Tribe To Invoke Immunity From IPR
Executive Summary
The tribe will move to get IPR proceedings dismissed, but the strategy isn't expected to affect ANDA litigation. Allergan's CEO said the company could use a similar approach with other patents and notes that other companies may follow.
You may also be interested in...
In Search Of Goodwill, Several Pharmas Commit To New Corporate ‘Statement Of Purpose’
The updated business principles may give pharma companies leverage, or at least talking points, as they continue to engage with the Trump administration on policies like the International Pricing Index and with US lawmakers on drug pricing legislation. J&J's Gorsky heads governing committee of multi-industry business group that revised its principles.
In Search Of Goodwill, Several Pharmas Commit To New Corporate ‘Statement Of Purpose’
The updated business principles may give pharma companies leverage, or at least talking points, as they continue to engage with the Trump administration on policies like the International Pricing Index and with US lawmakers on drug pricing legislation. J&J's Gorsky heads governing committee of multi-industry business group that revised its principles.
Bruised Over Humira Patent Games, AbbVie Sees Smoother Road With Botox
AbbVie’s proposed acquisition of Allergan unites two companies that have gained notoriety for their exhaustive and unconventional efforts, respectively, to extend the patents of key products.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: